Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Total Non-Current Liabilities (2019 - 2025)

Historic Total Non-Current Liabilities for Bolt Biotherapeutics (BOLT) over the last 7 years, with Q3 2025 value amounting to $32.8 million.

  • Bolt Biotherapeutics' Total Non-Current Liabilities fell 1202.05% to $32.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.8 million, marking a year-over-year decrease of 1202.05%. This contributed to the annual value of $42.4 million for FY2024, which is 971.49% down from last year.
  • As of Q3 2025, Bolt Biotherapeutics' Total Non-Current Liabilities stood at $32.8 million, which was down 1202.05% from $36.5 million recorded in Q2 2025.
  • In the past 5 years, Bolt Biotherapeutics' Total Non-Current Liabilities registered a high of $58.4 million during Q3 2021, and its lowest value of $21.1 million during Q1 2021.
  • Over the past 5 years, Bolt Biotherapeutics' median Total Non-Current Liabilities value was $47.1 million (recorded in 2023), while the average stood at $45.4 million.
  • In the last 5 years, Bolt Biotherapeutics' Total Non-Current Liabilities skyrocketed by 15723.85% in 2022 and then plummeted by 2103.21% in 2024.
  • Bolt Biotherapeutics' Total Non-Current Liabilities (Quarter) stood at $57.4 million in 2021, then fell by 1.97% to $56.3 million in 2022, then dropped by 16.46% to $47.0 million in 2023, then dropped by 9.71% to $42.4 million in 2024, then decreased by 22.66% to $32.8 million in 2025.
  • Its last three reported values are $32.8 million in Q3 2025, $36.5 million for Q2 2025, and $38.9 million during Q1 2025.